The present invention relates to bispecific chimeric polypeptide assembly compositions comprising bulking moieties linked to binding domains by cleavable release segments that, when cleaved are capable of concurrently binding effector T cells with targeted tumor or cancer cells and effecting cytolysis of the tumor cells or cancer cells. The invention also provides compositions and methods of making and using the cleavable chimeric polypeptide assembly compositions.

The present invention relates to exosomes, loaded with genetic material and methods of producing them and to the use of such exosomes for delivering genetic material in vivo, in particular the use of such exosomes in methods of gene therapy or gene silencing.

Described herein is an adeno-associated virus (AAV) capsid polypeptide bonded to a binding peptide including an amino acid sequence RGDX1X2X3X4, with X1 to X4 being independently selected amino acids, for use in treating and/or preventing a muscular disease and/or in muscle regeneration. Also described are polynucleotides, host cells, adeno-associated virus (AAV) capsids, pharmaceutical compositions, uses, and methods related to the AAV capsid polypeptide.

Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue.

The subject matter described herein is directed to methods of modifying the micro-environment of a target cell or The methods comprise systemically administering to a subject a composition comprising a vector, wherein the vector comprises a construct for the expression of a trap in the target cell, wherein the trap is expressed in the target cell thereby modifiying the micro-environment. Also described herein are methods of reducing metastasis of a cancer comprising, systemically administering to a subject suffering from the cancer, a composition comprising a vector, wherein the vector comprises a construct for the expression of a trap, wherein the trap is delivered to and then expressed in tissue susceptible to metastasis, wherein metastasis of the cancer to the tissue is reduced. Compositions for carrying out the methods are also described.

The present invention relates to the field of neurodegenerative processes and means to provide protection against the same. In particular, the present invention relates to polypeptides, fusion proteins, and other compounds interacting with the N-terminal domain of transient receptor potential melastatin subfamily member 4 (TRPM4), which are capable of interfering with NMDA receptor mediated neurotoxicity. The present invention also relates to nucleic acids encoding the aforementioned polypeptides or fusion proteins, compositions comprising the same and the use of said polypeptides, fusion proteins, and other compounds in methods for treating or preventing a disease of the human or animal body, for example in a method of treating diseases like Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD) or stroke.

In alternative embodiments, provided are compositions comprising chemically or structurally modified bacteriophages of the genus Caudovirales having an exterior or outer surface comprising at least one heterologous carbohydrate binding domain (CBD) comprising a lectin or a plurality of additional homologous CBDs, or more CBDs than found on a comparable wild type (WT) bacteriophage.

The invention relates to a synthetic fusion protein having high antimicrobial activity. In particular, the invention relates to the use of said protein to eliminate pathogenic microorganisms from environments and surfaces. In particular, the synthetic fusion protein object of the present invention can be used in the preparation of disinfectant solutions that can be used in the outpatient, hospital and domestic field, in high traffic environments, in filters of air inlet and extraction systems or air conditioners or air treatment unit ATU, in environments used for food preparation. In general, in all those areas where it is necessary to adopt antimicrobial prophylaxis directed against gram+bacteria, viruses, mycoplasma and fungi.

The present invention relates to T cell receptors (TCRs) that bind the HLA-A*02 restricted peptide GVYDGREHTV (SEQ ID NO: 1) derived from the germline cancer antigen MAGE A4. Said TCRs may comprise non-natural mutations within the alpha and/or beta variable domains relative to a native MAGE A4 TCR. The TCRs of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of malignant disease.

Disclosed by the present application are an antibody library construction method and an application thereof. The method comprises the following steps: inserting a first element and a second element into a same vector or different vectors, and transfecting the vectors into the cells to obtain an antibody expression cell library, i.e., the antibody library. The first element comprises CIS activators and selection marker genes; the second element comprises extracellular antibody library coding domain, Notch nuclear structure domain and intracellular transcription structure domain.